Clinical-stage biotechnology company
Appears in 1 story · Last updated Oct 25, 2026
Lead candidate PROT-001 cleared for pivotal trial
The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. Protego says the study is planned to begin in the first quarter of 2027.
Updated Oct 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
